ArticleJournal of nanobiotechnology2025
Enhanced multienzyme catalytic activity of Mn MOF induced by bioligands for efficient tumor therapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Manganese Ion-Based NanoPlatforms for Tumor Theranostics.Advanced healthcare materials · 2026Review
- NIR-II Type I AIE Photosensitiser-Functionalized MOF-Cu Nanoplatform Promotes Ferroptosis and Cuproptosis for Antitumor Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Advances and Prospects in MOF-Based Platforms for Tumor Hyperthermia.Bioengineering (Basel, Switzerland) · 2026Review
- Porphyrin oriented bimetallic sonodynamic MOF for enhanced ferroptosis and cGAS-STING pathway mediated antitumor immunotherapy.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanozymes, as substitutes for natural enzymes, are widely used in various fields, such as cancer treatment. However, most nanozymes have low catalytic activity and selectivity, greatly limiting their clinical applications. Here, we propose a new design concept for nanozymes: modifying nanozymes with suitable multifunctional bioligands. This approach not only endows multiple biological functions but also enhances the multienzyme activity of nanozymes and avoids the effect of surface modification on nanozyme activity. In brief, this paper uses multifunctional bioligands to modify Mn MOF to obtain the nanozyme HPMZIF, which exhibits excellent biocompatibility and tumor-targeting ability. Interestingly, polyethyleneimine (PEI) modification not only effectively enhances the biocompatibility of Mn MOF, but also increases the peroxidase (POD)-, oxidase (OXD)- and glutathione peroxidase (GPx)-like activities of Mn MOF nanozymes. Furthermore, hyaluronic acid (HA) modification imparts the Mn MOF nanozymes with tumor targeting ability and enhanced the OXD- and GPx-like activities of the Mn MOF nanozymes. Ultimately, our nanoplatform cascade enhanced pyroptosis, chemotherapy, and chemodynamic therapy (CDT), significantly inhibiting the growth of 4T1 xenograft tumors. In summary, this work provides a feasible strategy for designing nanozymes with high activity and diverse biological functions, and offers new perspectives on the clinical translation of nanozymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.